Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
Phase 1 Withdrawn
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
Phase 1/2 Withdrawn
Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up
Phase NA Withdrawn
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Phase 1 Withdrawn
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Phase 1 Withdrawn
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Withdrawn
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Phase 1 Withdrawn
Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth
Withdrawn
Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
Phase 1 Withdrawn
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
Phase 1 Withdrawn
HEM-iSMART A
Phase 1/2 Withdrawn
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
Phase 1 Withdrawn
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
Phase 3 Withdrawn
SABRE
Phase 2 Withdrawn
Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy
Phase NA Withdrawn
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
Phase 2 Withdrawn
STP-LYM-01
Phase 1/2 Withdrawn
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Phase 1/2 Withdrawn
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Phase 2 Withdrawn
Collecting and Storing Blood Samples From Patients With Cancer
Withdrawn
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Phase 1 Withdrawn
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
Phase 2 Withdrawn
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
Phase 1 Withdrawn
Bone Marrow Transplantation in Treating Patients With Leukemia
Phase 3 Withdrawn
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Withdrawn
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase 1/2 Withdrawn
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Phase 1/2 Withdrawn
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
Phase 2 Withdrawn
Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study
Phase NA Withdrawn
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Phase 2 Withdrawn
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
Phase 1 Withdrawn
Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center
Withdrawn
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
Phase 1 Withdrawn
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
Phase 1/2 Withdrawn
DETECS
Withdrawn
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Phase 2 Withdrawn
Randomized Trial of Mobilized Blood/Marrow Versus Blood Transplant
Phase NA Withdrawn
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
Phase 1 Withdrawn
A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia
Phase NA Withdrawn
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Phase NA Withdrawn
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
Phase 2 Withdrawn
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
Phase 2 Withdrawn
Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation
Phase 1/2 Withdrawn
CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation
Phase 1 Withdrawn
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
Withdrawn
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Phase 1 Withdrawn
Acupuncture for Mucositis Pain in Cancer Care
Phase NA Withdrawn
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
Phase 1/2 Withdrawn
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
Phase 2 Withdrawn